fbpx
Wikipedia

Interleukin 23

January 01, 1970

Interleukin 23 (IL-23) is a heterodimeric cytokine composed of an IL-12B (IL-12p40) subunit (which is shared with IL-12) and an IL-23A (IL-23p19) subunit.[1] IL-23 is part of the IL-12 family of cytokines.[2] The functional receptor for IL-23 (the IL-23 receptor) consists of a heterodimer between IL-12Rβ1 and IL-23R.[3]

IL12B
Crystal structure of IL-12B
Identifiers
SymbolIL12B
Alt. symbolsCLMF2, NKSF2, p40
NCBI gene3593
HGNC5970
OMIM161561
PDB1F42
RefSeqNM_002187
UniProtP29460
Other data
LocusChr. 5 q31.1-33.1
Search for
StructuresSwiss-model
DomainsInterPro
interleukin 23, alpha subunit p19
Identifiers
SymbolIL23A
NCBI gene51561
HGNC15488
RefSeqNM_016584
UniProtQ9NPF7
Other data
LocusChr. 12 q13.13
Search for
StructuresSwiss-model
DomainsInterPro

Discovery edit

IL-23 was first described by Robert Kastelein and colleagues at the DNAX research institute using a combination of computational, biochemical and cellular immunology approaches.[1]

Function edit

IL-23 is an inflammatory cytokine. It has been shown to be a key cytokine for T helper type 17 cell (Th17 cell) maintenance and expansion. Polarisation to a Th17 phenotype is triggered by IL-6 and TGF-β, which activate the Th17 transcription factor RORγt. IL-23 stabilises RORγt and thus enables Th17 cells to release their effector cytokines, such as IL-17, IL-21, IL-22 and GM-CSF, which mediate protection against extracellular fungi and bacteria and participate in barrier immunity.[4] Effects similar to those IL-23 has on Th17 cells were described for type 3 innate lymphoid cells, which actively secrete Th17 cytokines upon IL-23 stimulation.[5] Natural killer cells also express the IL-23 receptor. They respond with increased interferon-γ secretion and enhanced antibody-dependent cellular cytotoxicity. IL-23 also induces proliferation of CD4 memory T cells (but not naïve T cells).[6] Besides its proinflammatory effects, IL-23 promotes angiogenesis.[7] 

IL-23 is mainly secreted by activated dendritic cells, macrophages or monocytes. Innate lymphoid cells and γδ T cells also produce IL-23.[2] B cells produce IL-23 through B cell antigen receptor signaling.[8] Secretion is stimulated by an antigen stimulus recognised by a pattern recognition receptor.[9] IL-23 imbalance and increase is associated with autoimmune diseases and cancer. It is thus a target for therapeutic research.[4] IL-23 expression by dendritic cells is further induced by thymic stromal lymphopoietin, a proallergic cytokine expressed by keratinocytes that is elevated in psoriatic lesions.[10] In the pathogenesis of psoriasis, dermal dendritic cells are stimulated to release IL-23 by nociceptive neurons.[11] IL-23 is also elevated during bacterial meningitis, leading to epithelial dysregulation and inflammation.[12]

Mycobacterium avium subspecies paratuberculosis-stimulated monocyte-derived macrophages are one of the contributors of IL-23, and thus cattle with Johne's disease have elevated IL-23.[13]

Prior to the discovery of IL-23, IL-12 had been proposed to represent a key mediator of inflammation in mouse models of inflammation.[14] However, many studies aimed at assessing the role of IL-12 by pharmacological blockade had targeted IL-12B, and were therefore not as specific as thought. Studies which blocked the function of IL-12A did not produce the same results as those targeting IL-12B, as would have been expected if both subunits formed part of IL-12 only.[15]

The discovery of an additional potential binding partner for IL-12B led to a reassessment of this role for IL-12. Studies in experimental autoimmune encephalomyelitis, a mouse model of multiple sclerosis, showed that IL-23 was responsible for the inflammation observed, not IL-12 as previously thought.[16] Subsequently, IL-23 was shown to facilitate development of inflammation in numerous other models of immune pathology where IL-12 had previously been implicated, including models of arthritis,[17] intestinal inflammation,[18][19][20] and psoriasis.[21] Low concentrations of IL-23 support lung tumor growth whereas high concentrations inhibit proliferation of lung cancer cells.[22] IL-23 and IL-23R were identified in serum from patients with non-small-cell lung cancer and have been proposed as prognostic serum markers.[23] IL-23 can also promote progression of cardiovascular diseases such as atherosclerosis, hypertension, aortic dissection, cardiac hypertrophy, myocardial infarction and acute cardiac injury[citation needed]. In brain, IL-23 is able to activate γδ T cells to increase their expression of IL-17, which contributes to the inflammatory response and thus plays a key role in secondary brain injury after spontaneous intracerebral hemorrhage.[24]

Monoclonal antibody drugs edit

IL-23 is one of the therapeutic targets to treat the inflammatory diseases.[25] Ustekinumab, a monoclonal antibody directed against this cytokine, is used to treat certain autoimmune conditions.[26] Guselkumab is another monoclonal antibody against IL-23. Blocking IL-23 can slow clinical manifestation of psoriasis, indirectly affecting Th17 immune response and production of IL-17.[27] Ixekizumab, an IL-17A antagonist, has been reported to have faster onset of action in treatment of psoriasis than guselkumab, tildrakizumab or risankizumab, which are inhibitors of the p19 subunit of IL-23.[28] However, risankizumab has been shown to have the best treatment results for psoriasis in comparison with other IL-23 inhibitors.[29] Adnectin-2 binds to IL-23 and competes with IL-23–IL-23R binding.[25]

Signalling edit

The IL-23 heterodimer binds the receptor complex: the p19 subunit binds IL-23R while the p40 subunit binds IL-12RB1. Receptor binding leads to recruitment of Janus kinase 2 and Tyrosine kinase 2 kinases. Janus kinase 2 and Tyrosine kinase 2 transduce the signal and phosphorylate STAT3 and STAT4. STATs dimerise and activate transcription of target genes in nucleus. STAT3 is responsible for key Th17 development attributes such as RORγt expression and transcription of Th17 cytokines.[4] 

References edit

  1. ^ a b Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, et al. (November 2000). "Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12". Immunity. 13 (5): 715–25. doi:10.1016/S1074-7613(00)00070-4. PMID 11114383.
  2. ^ a b Cauli A, Piga M, Floris A, Mathieu A (2015-10-01). "Current perspective on the role of the interleukin-23/interleukin-17 axis in inflammation and disease (chronic arthritis and psoriasis)". ImmunoTargets and Therapy. 4: 185–90. doi:10.2147/ITT.S62870. PMC 4918258. PMID 27471723.
  3. ^ Parham C, Chirica M, Timans J, Vaisberg E, Travis M, Cheung J, et al. (June 2002). "A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R". Journal of Immunology. 168 (11): 5699–708. doi:10.4049/jimmunol.168.11.5699. PMID 12023369.
  4. ^ a b c Tang C, Chen S, Qian H, Huang W (February 2012). "Interleukin-23: as a drug target for autoimmune inflammatory diseases". Immunology. 135 (2): 112–24. doi:10.1111/j.1365-2567.2011.03522.x. PMC 3277713. PMID 22044352.
  5. ^ Zeng B, Shi S, Ashworth G, Dong C, Liu J, Xing F (April 2019). "ILC3 function as a double-edged sword in inflammatory bowel diseases". Cell Death & Disease. 10 (4): 315. doi:10.1038/s41419-019-1540-2. PMC 6453898. PMID 30962426.
  6. ^ Li Y, Wang H, Lu H, Hua S (2016). "Regulation of Memory T Cells by Interleukin-23". International Archives of Allergy and Immunology. 169 (3): 157–62. doi:10.1159/000445834. PMID 27100864. S2CID 24274565.
  7. ^ Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K, et al. (July 2006). "IL-23 promotes tumour incidence and growth". Nature. 442 (7101): 461–5. Bibcode:2006Natur.442..461L. doi:10.1038/nature04808. PMID 16688182. S2CID 4431794.
  8. ^ Gagro A, Servis D, Cepika AM, Toellner KM, Grafton G, Taylor DR, et al. (May 2006). "Type I cytokine profiles of human naïve and memory B lymphocytes: a potential for memory cells to impact polarization". Immunology. 118 (1): 66–77. doi:10.1111/j.1365-2567.2006.02342.x. PMC 1782263. PMID 16630024.
  9. ^ Re F, Strominger JL (October 2001). "Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells". The Journal of Biological Chemistry. 276 (40): 37692–9. doi:10.1074/jbc.M105927200. PMID 11477091.
  10. ^ Volpe E, Pattarini L, Martinez-Cingolani C, Meller S, Donnadieu MH, Bogiatzi SI, et al. (August 2014). "Thymic stromal lymphopoietin links keratinocytes and dendritic cell-derived IL-23 in patients with psoriasis". The Journal of Allergy and Clinical Immunology. 134 (2): 373–81. doi:10.1016/j.jaci.2014.04.022. PMID 24910175.
  11. ^ Riol-Blanco L, Ordovas-Montanes J, Perro M, Naval E, Thiriot A, Alvarez D, et al. (June 2014). "Nociceptive sensory neurons drive interleukin-23-mediated psoriasiform skin inflammation". Nature. 510 (7503): 157–61. Bibcode:2014Natur.510..157R. doi:10.1038/nature13199. PMC 4127885. PMID 24759321.
  12. ^ Srinivasan L, Kilpatrick L, Shah SS, Abbasi S, Harris MC (2018-02-02). "Elevations of novel cytokines in bacterial meningitis in infants". PLOS ONE. 13 (2): e0181449. Bibcode:2018PLoSO..1381449S. doi:10.1371/journal.pone.0181449. PMC 5796685. PMID 29394248.
  13. ^ DeKuiper JL, Cooperider HE, Lubben N, Ancel CM, Coussens PM (2020). "paratuberculosis Drives an Innate Th17-Like T Cell Response Regardless of the Presence of Antigen-Presenting Cells". Frontiers in Veterinary Science. 7: 108. doi:10.3389/fvets.2020.00108. PMC 7089878. PMID 32258066.
  14. ^ Leonard JP, Waldburger KE, Goldman SJ (January 1995). "Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12". The Journal of Experimental Medicine. 181 (1): 381–6. doi:10.1084/jem.181.1.381. PMC 2191822. PMID 7528773.
  15. ^ Becher B, Durell BG, Noelle RJ (August 2002). "Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12". The Journal of Clinical Investigation. 110 (4): 493–7. doi:10.1172/JCI15751. PMC 150420. PMID 12189243.
  16. ^ Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, et al. (February 2003). "Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain". Nature. 421 (6924): 744–8. Bibcode:2003Natur.421..744C. doi:10.1038/nature01355. PMID 12610626. S2CID 4380302.
  17. ^ Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan T, Kastelein RA, et al. (December 2003). "Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation". The Journal of Experimental Medicine. 198 (12): 1951–7. doi:10.1084/jem.20030896. PMC 2194162. PMID 14662908.
  18. ^ Yen D, Cheung J, Scheerens H, Poulet F, McClanahan T, McKenzie B, et al. (May 2006). "IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6". The Journal of Clinical Investigation. 116 (5): 1310–6. doi:10.1172/JCI21404. PMC 1451201. PMID 16670770.
  19. ^ Kullberg MC, Jankovic D, Feng CG, Hue S, Gorelick PL, McKenzie BS, et al. (October 2006). "IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis". The Journal of Experimental Medicine. 203 (11): 2485–94. doi:10.1084/jem.20061082. PMC 2118119. PMID 17030948.
  20. ^ Hue S, Ahern P, Buonocore S, Kullberg MC, Cua DJ, McKenzie BS, et al. (October 2006). "Interleukin-23 drives innate and T cell-mediated intestinal inflammation". The Journal of Experimental Medicine. 203 (11): 2473–83. doi:10.1084/jem.20061099. PMC 2118132. PMID 17030949.
  21. ^ Chan JR, Blumenschein W, Murphy E, Diveu C, Wiekowski M, Abbondanzo S, et al. (November 2006). "IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis". The Journal of Experimental Medicine. 203 (12): 2577–87. doi:10.1084/jem.20060244. PMC 2118145. PMID 17074928.
  22. ^ Li J, Zhang L, Zhang J, Wei Y, Li K, Huang L, et al. (March 2013). "Interleukin 23 regulates proliferation of lung cancer cells in a concentration-dependent way in association with the interleukin-23 receptor". Carcinogenesis. 34 (3): 658–66. doi:10.1093/carcin/bgs384. PMID 23250909.
  23. ^ Liu D, Xing S, Wang W, Huang X, Lin H, Chen Y, et al. (April 2020). "Prognostic value of serum soluble interleukin-23 receptor and related T-helper 17 cell cytokines in non-small cell lung carcinoma". Cancer Science. 111 (4): 1093–1102. doi:10.1111/cas.14343. PMC 7156824. PMID 32020720.
  24. ^ Zhu H, Wang Z, Yu J, Yang X, He F, Liu Z, Che F, Chen X, Ren H, Hong M, Wang J (March 2019). "Role and mechanisms of cytokines in the secondary brain injury after intracerebral hemorrhage". Prog. Neurobiol. 178: 101610. doi:10.1016/j.pneurobio.2019.03.003. PMID 30923023. S2CID 85495400.
  25. ^ a b Iacob RE, Krystek SR, Huang RY, Wei H, Tao L, Lin Z, et al. (April 2015). "Hydrogen/deuterium exchange mass spectrometry applied to IL-23 interaction characteristics: potential impact for therapeutics". Expert Review of Proteomics. 12 (2): 159–69. doi:10.1586/14789450.2015.1018897. PMC 4409866. PMID 25711416.
  26. ^ Cingoz O (2009). "Ustekinumab". mAbs. 1 (3): 216–21. doi:10.4161/mabs.1.3.8593. PMC 2726595. PMID 20069753.
  27. ^ Warren RB, Gooderham M, Burge R, Zhu B, Amato D, Liu KH, et al. (May 2020). "Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis". Journal of the American Academy of Dermatology. 82 (5): 1138–1149. doi:10.1016/j.jaad.2019.12.038. PMID 31884091.
  28. ^ Gottlieb AB, Saure D, Wilhelm S, Dossenbach M, Schuster C, Smith SD, et al. (April 2020). "Indirect comparisons of ixekizumab versus three interleukin-23 p19 inhibitors in patients with moderate-to-severe plaque psoriasis - efficacy findings up to week 12". The Journal of Dermatological Treatment. 33 (1): 54–61. doi:10.1080/09546634.2020.1747592. PMID 32299269.
  29. ^ Yasmeen N, Sawyer LM, Malottki K, Levin LÅ, Didriksen Apol E, Jemec GB (April 2020). "Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year". The Journal of Dermatological Treatment. 33 (1): 204–218. doi:10.1080/09546634.2020.1743811. PMID 32202445.

January 01, 1970
interleukin, heterodimeric, cytokine, composed, 12p40, subunit, which, shared, with, 23p19, subunit, part, family, cytokines, functional, receptor, receptor, consists, heterodimer, between, 12rβ1, il12bcrystal, structure, 12bidentifierssymbolil12balt, symbolsc. Interleukin 23 IL 23 is a heterodimeric cytokine composed of an IL 12B IL 12p40 subunit which is shared with IL 12 and an IL 23A IL 23p19 subunit 1 IL 23 is part of the IL 12 family of cytokines 2 The functional receptor for IL 23 the IL 23 receptor consists of a heterodimer between IL 12Rb1 and IL 23R 3 IL12BCrystal structure of IL 12BIdentifiersSymbolIL12BAlt symbolsCLMF2 NKSF2 p40NCBI gene3593HGNC5970OMIM161561PDB1F42RefSeqNM 002187UniProtP29460Other dataLocusChr 5 q31 1 33 1Search forStructuresSwiss modelDomainsInterPro interleukin 23 alpha subunit p19IdentifiersSymbolIL23ANCBI gene51561HGNC15488RefSeqNM 016584UniProtQ9NPF7Other dataLocusChr 12 q13 13Search forStructuresSwiss modelDomainsInterPro Contents 1 Discovery 2 Function 2 1 Monoclonal antibody drugs 3 Signalling 4 ReferencesDiscovery editIL 23 was first described by Robert Kastelein and colleagues at the DNAX research institute using a combination of computational biochemical and cellular immunology approaches 1 Function editIL 23 is an inflammatory cytokine It has been shown to be a key cytokine for T helper type 17 cell Th17 cell maintenance and expansion Polarisation to a Th17 phenotype is triggered by IL 6 and TGF b which activate the Th17 transcription factor RORgt IL 23 stabilises RORgt and thus enables Th17 cells to release their effector cytokines such as IL 17 IL 21 IL 22 and GM CSF which mediate protection against extracellular fungi and bacteria and participate in barrier immunity 4 Effects similar to those IL 23 has on Th17 cells were described for type 3 innate lymphoid cells which actively secrete Th17 cytokines upon IL 23 stimulation 5 Natural killer cells also express the IL 23 receptor They respond with increased interferon g secretion and enhanced antibody dependent cellular cytotoxicity IL 23 also induces proliferation of CD4 memory T cells but not naive T cells 6 Besides its proinflammatory effects IL 23 promotes angiogenesis 7 IL 23 is mainly secreted by activated dendritic cells macrophages or monocytes Innate lymphoid cells and gd T cells also produce IL 23 2 B cells produce IL 23 through B cell antigen receptor signaling 8 Secretion is stimulated by an antigen stimulus recognised by a pattern recognition receptor 9 IL 23 imbalance and increase is associated with autoimmune diseases and cancer It is thus a target for therapeutic research 4 IL 23 expression by dendritic cells is further induced by thymic stromal lymphopoietin a proallergic cytokine expressed by keratinocytes that is elevated in psoriatic lesions 10 In the pathogenesis of psoriasis dermal dendritic cells are stimulated to release IL 23 by nociceptive neurons 11 IL 23 is also elevated during bacterial meningitis leading to epithelial dysregulation and inflammation 12 Mycobacterium avium subspecies paratuberculosis stimulated monocyte derived macrophages are one of the contributors of IL 23 and thus cattle with Johne s disease have elevated IL 23 13 Prior to the discovery of IL 23 IL 12 had been proposed to represent a key mediator of inflammation in mouse models of inflammation 14 However many studies aimed at assessing the role of IL 12 by pharmacological blockade had targeted IL 12B and were therefore not as specific as thought Studies which blocked the function of IL 12A did not produce the same results as those targeting IL 12B as would have been expected if both subunits formed part of IL 12 only 15 The discovery of an additional potential binding partner for IL 12B led to a reassessment of this role for IL 12 Studies in experimental autoimmune encephalomyelitis a mouse model of multiple sclerosis showed that IL 23 was responsible for the inflammation observed not IL 12 as previously thought 16 Subsequently IL 23 was shown to facilitate development of inflammation in numerous other models of immune pathology where IL 12 had previously been implicated including models of arthritis 17 intestinal inflammation 18 19 20 and psoriasis 21 Low concentrations of IL 23 support lung tumor growth whereas high concentrations inhibit proliferation of lung cancer cells 22 IL 23 and IL 23R were identified in serum from patients with non small cell lung cancer and have been proposed as prognostic serum markers 23 IL 23 can also promote progression of cardiovascular diseases such as atherosclerosis hypertension aortic dissection cardiac hypertrophy myocardial infarction and acute cardiac injury citation needed In brain IL 23 is able to activate gd T cells to increase their expression of IL 17 which contributes to the inflammatory response and thus plays a key role in secondary brain injury after spontaneous intracerebral hemorrhage 24 Monoclonal antibody drugs edit IL 23 is one of the therapeutic targets to treat the inflammatory diseases 25 Ustekinumab a monoclonal antibody directed against this cytokine is used to treat certain autoimmune conditions 26 Guselkumab is another monoclonal antibody against IL 23 Blocking IL 23 can slow clinical manifestation of psoriasis indirectly affecting Th17 immune response and production of IL 17 27 Ixekizumab an IL 17A antagonist has been reported to have faster onset of action in treatment of psoriasis than guselkumab tildrakizumab or risankizumab which are inhibitors of the p19 subunit of IL 23 28 However risankizumab has been shown to have the best treatment results for psoriasis in comparison with other IL 23 inhibitors 29 Adnectin 2 binds to IL 23 and competes with IL 23 IL 23R binding 25 Signalling editThe IL 23 heterodimer binds the receptor complex the p19 subunit binds IL 23R while the p40 subunit binds IL 12RB1 Receptor binding leads to recruitment of Janus kinase 2 and Tyrosine kinase 2 kinases Janus kinase 2 and Tyrosine kinase 2 transduce the signal and phosphorylate STAT3 and STAT4 STATs dimerise and activate transcription of target genes in nucleus STAT3 is responsible for key Th17 development attributes such as RORgt expression and transcription of Th17 cytokines 4 References edit a b Oppmann B Lesley R Blom B Timans JC Xu Y Hunte B et al November 2000 Novel p19 protein engages IL 12p40 to form a cytokine IL 23 with biological activities similar as well as distinct from IL 12 Immunity 13 5 715 25 doi 10 1016 S1074 7613 00 00070 4 PMID 11114383 a b Cauli A Piga M Floris A Mathieu A 2015 10 01 Current perspective on the role of the interleukin 23 interleukin 17 axis in inflammation and disease chronic arthritis and psoriasis ImmunoTargets and Therapy 4 185 90 doi 10 2147 ITT S62870 PMC 4918258 PMID 27471723 Parham C Chirica M Timans J Vaisberg E Travis M Cheung J et al June 2002 A receptor for the heterodimeric cytokine IL 23 is composed of IL 12Rbeta1 and a novel cytokine receptor subunit IL 23R Journal of Immunology 168 11 5699 708 doi 10 4049 jimmunol 168 11 5699 PMID 12023369 a b c Tang C Chen S Qian H Huang W February 2012 Interleukin 23 as a drug target for autoimmune inflammatory diseases Immunology 135 2 112 24 doi 10 1111 j 1365 2567 2011 03522 x PMC 3277713 PMID 22044352 Zeng B Shi S Ashworth G Dong C Liu J Xing F April 2019 ILC3 function as a double edged sword in inflammatory bowel diseases Cell Death amp Disease 10 4 315 doi 10 1038 s41419 019 1540 2 PMC 6453898 PMID 30962426 Li Y Wang H Lu H Hua S 2016 Regulation of Memory T Cells by Interleukin 23 International Archives of Allergy and Immunology 169 3 157 62 doi 10 1159 000445834 PMID 27100864 S2CID 24274565 Langowski JL Zhang X Wu L Mattson JD Chen T Smith K et al July 2006 IL 23 promotes tumour incidence and growth Nature 442 7101 461 5 Bibcode 2006Natur 442 461L doi 10 1038 nature04808 PMID 16688182 S2CID 4431794 Gagro A Servis D Cepika AM Toellner KM Grafton G Taylor DR et al May 2006 Type I cytokine profiles of human naive and memory B lymphocytes a potential for memory cells to impact polarization Immunology 118 1 66 77 doi 10 1111 j 1365 2567 2006 02342 x PMC 1782263 PMID 16630024 Re F Strominger JL October 2001 Toll like receptor 2 TLR2 and TLR4 differentially activate human dendritic cells The Journal of Biological Chemistry 276 40 37692 9 doi 10 1074 jbc M105927200 PMID 11477091 Volpe E Pattarini L Martinez Cingolani C Meller S Donnadieu MH Bogiatzi SI et al August 2014 Thymic stromal lymphopoietin links keratinocytes and dendritic cell derived IL 23 in patients with psoriasis The Journal of Allergy and Clinical Immunology 134 2 373 81 doi 10 1016 j jaci 2014 04 022 PMID 24910175 Riol Blanco L Ordovas Montanes J Perro M Naval E Thiriot A Alvarez D et al June 2014 Nociceptive sensory neurons drive interleukin 23 mediated psoriasiform skin inflammation Nature 510 7503 157 61 Bibcode 2014Natur 510 157R doi 10 1038 nature13199 PMC 4127885 PMID 24759321 Srinivasan L Kilpatrick L Shah SS Abbasi S Harris MC 2018 02 02 Elevations of novel cytokines in bacterial meningitis in infants PLOS ONE 13 2 e0181449 Bibcode 2018PLoSO 1381449S doi 10 1371 journal pone 0181449 PMC 5796685 PMID 29394248 DeKuiper JL Cooperider HE Lubben N Ancel CM Coussens PM 2020 paratuberculosis Drives an Innate Th17 Like T Cell Response Regardless of the Presence of Antigen Presenting Cells Frontiers in Veterinary Science 7 108 doi 10 3389 fvets 2020 00108 PMC 7089878 PMID 32258066 Leonard JP Waldburger KE Goldman SJ January 1995 Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12 The Journal of Experimental Medicine 181 1 381 6 doi 10 1084 jem 181 1 381 PMC 2191822 PMID 7528773 Becher B Durell BG Noelle RJ August 2002 Experimental autoimmune encephalitis and inflammation in the absence of interleukin 12 The Journal of Clinical Investigation 110 4 493 7 doi 10 1172 JCI15751 PMC 150420 PMID 12189243 Cua DJ Sherlock J Chen Y Murphy CA Joyce B Seymour B et al February 2003 Interleukin 23 rather than interleukin 12 is the critical cytokine for autoimmune inflammation of the brain Nature 421 6924 744 8 Bibcode 2003Natur 421 744C doi 10 1038 nature01355 PMID 12610626 S2CID 4380302 Murphy CA Langrish CL Chen Y Blumenschein W McClanahan T Kastelein RA et al December 2003 Divergent pro and antiinflammatory roles for IL 23 and IL 12 in joint autoimmune inflammation The Journal of Experimental Medicine 198 12 1951 7 doi 10 1084 jem 20030896 PMC 2194162 PMID 14662908 Yen D Cheung J Scheerens H Poulet F McClanahan T McKenzie B et al May 2006 IL 23 is essential for T cell mediated colitis and promotes inflammation via IL 17 and IL 6 The Journal of Clinical Investigation 116 5 1310 6 doi 10 1172 JCI21404 PMC 1451201 PMID 16670770 Kullberg MC Jankovic D Feng CG Hue S Gorelick PL McKenzie BS et al October 2006 IL 23 plays a key role in Helicobacter hepaticus induced T cell dependent colitis The Journal of Experimental Medicine 203 11 2485 94 doi 10 1084 jem 20061082 PMC 2118119 PMID 17030948 Hue S Ahern P Buonocore S Kullberg MC Cua DJ McKenzie BS et al October 2006 Interleukin 23 drives innate and T cell mediated intestinal inflammation The Journal of Experimental Medicine 203 11 2473 83 doi 10 1084 jem 20061099 PMC 2118132 PMID 17030949 Chan JR Blumenschein W Murphy E Diveu C Wiekowski M Abbondanzo S et al November 2006 IL 23 stimulates epidermal hyperplasia via TNF and IL 20R2 dependent mechanisms with implications for psoriasis pathogenesis The Journal of Experimental Medicine 203 12 2577 87 doi 10 1084 jem 20060244 PMC 2118145 PMID 17074928 Li J Zhang L Zhang J Wei Y Li K Huang L et al March 2013 Interleukin 23 regulates proliferation of lung cancer cells in a concentration dependent way in association with the interleukin 23 receptor Carcinogenesis 34 3 658 66 doi 10 1093 carcin bgs384 PMID 23250909 Liu D Xing S Wang W Huang X Lin H Chen Y et al April 2020 Prognostic value of serum soluble interleukin 23 receptor and related T helper 17 cell cytokines in non small cell lung carcinoma Cancer Science 111 4 1093 1102 doi 10 1111 cas 14343 PMC 7156824 PMID 32020720 Zhu H Wang Z Yu J Yang X He F Liu Z Che F Chen X Ren H Hong M Wang J March 2019 Role and mechanisms of cytokines in the secondary brain injury after intracerebral hemorrhage Prog Neurobiol 178 101610 doi 10 1016 j pneurobio 2019 03 003 PMID 30923023 S2CID 85495400 a b Iacob RE Krystek SR Huang RY Wei H Tao L Lin Z et al April 2015 Hydrogen deuterium exchange mass spectrometry applied to IL 23 interaction characteristics potential impact for therapeutics Expert Review of Proteomics 12 2 159 69 doi 10 1586 14789450 2015 1018897 PMC 4409866 PMID 25711416 Cingoz O 2009 Ustekinumab mAbs 1 3 216 21 doi 10 4161 mabs 1 3 8593 PMC 2726595 PMID 20069753 Warren RB Gooderham M Burge R Zhu B Amato D Liu KH et al May 2020 Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks Results from a network meta analysis Journal of the American Academy of Dermatology 82 5 1138 1149 doi 10 1016 j jaad 2019 12 038 PMID 31884091 Gottlieb AB Saure D Wilhelm S Dossenbach M Schuster C Smith SD et al April 2020 Indirect comparisons of ixekizumab versus three interleukin 23 p19 inhibitors in patients with moderate to severe plaque psoriasis efficacy findings up to week 12 The Journal of Dermatological Treatment 33 1 54 61 doi 10 1080 09546634 2020 1747592 PMID 32299269 Yasmeen N Sawyer LM Malottki K Levin LA Didriksen Apol E Jemec GB April 2020 Targeted therapies for patients with moderate to severe psoriasis a systematic review and network meta analysis of PASI response at 1 year The Journal of Dermatological Treatment 33 1 204 218 doi 10 1080 09546634 2020 1743811 PMID 32202445 Retrieved from https en wikipedia org w index php title Interleukin 23 amp oldid 1187177288, wikipedia, wiki, book, books, library,

article

, read, download, free, free download, mp3, video, mp4, 3gp, jpg, jpeg, gif, png, picture, music, song, movie, book, game, games.